NASDAQ:EGRX - Eagle Pharmaceuticals Stock Price, Forecast & News

Eagle Pharmaceuticals trades on the NASDAQ under the ticker symbol "EGRX."

Eagle Pharmaceuticals Inc (NASDAQ:EGRX) released its quarterly earnings data on Tuesday, November, 12th. The specialty pharmaceutical company reported $0.26 earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of $0.43 by $0.17. The specialty pharmaceutical company earned $41.10 million during the quarter, compared to analyst estimates of $45.44 million. Eagle Pharmaceuticals had a net margin of 12.72% and a return on equity of 16.07%. The firm's quarterly revenue was down 19.9% compared to the same quarter last year. During the same quarter in the prior year, the company posted $1.18 EPS. View Eagle Pharmaceuticals' Earnings History.

Eagle Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Monday, March 2nd 2020. View Earnings Estimates for Eagle Pharmaceuticals.

Eagle Pharmaceuticals will be holding an earnings conference call on Monday, March 2nd at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

3 brokers have issued twelve-month price targets for Eagle Pharmaceuticals' shares. Their forecasts range from $50.00 to $66.00. On average, they expect Eagle Pharmaceuticals' stock price to reach $58.00 in the next year. This suggests a possible upside of 25.2% from the stock's current price. View Analyst Price Targets for Eagle Pharmaceuticals.

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Eagle Pharmaceuticals in the last year. There are currently 2 hold ratings and 1 buy rating for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Eagle Pharmaceuticals.

Headlines about EGRX stock have been trending extremely negative this week, according to InfoTrie Sentiment Analysis. The research group ranks the sentiment of news coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. Eagle Pharmaceuticals earned a media sentiment score of -4.4 on InfoTrie's scale. They also assigned media stories about the specialty pharmaceutical company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an effect on the stock's share price in the near term. View News Stories for Eagle Pharmaceuticals.

Eagle Pharmaceuticals saw a increase in short interest in February. As of February 14th, there was short interest totalling 1,870,000 shares, an increase of 8.1% from the January 30th total of 1,730,000 shares. Based on an average trading volume of 143,500 shares, the days-to-cover ratio is presently 13.0 days. Currently, 14.4% of the shares of the company are short sold. View Eagle Pharmaceuticals' Current Options Chain.

Some companies that are related to Eagle Pharmaceuticals include Amicus Therapeutics (FOLD), ChemoCentryx (CCXI), SAGE Therapeutics (SAGE), ArQule (ARQL), Uniqure (QURE), Principia Biopharma (PRNB), Synthorx (THOR), Ra Pharmaceuticals (RARX), Arena Pharmaceuticals (ARNA), Biohaven Pharmaceutical (BHVN), Insmed (INSM), Forty Seven (FTSV), Cambrex (CBM), Aurinia Pharmaceuticals (AUPH) and Prestige Consumer Healthcare (PBH).

Based on aggregate information from My MarketBeat watchlists, some companies that other Eagle Pharmaceuticals investors own include Gilead Sciences (GILD), Exelixis (EXEL), Teekay Tankers (TNK), Celgene (CELG), Intercept Pharmaceuticals (ICPT), AbbVie (ABBV), GW Pharmaceuticals PLC- (GWPH), bluebird bio (BLUE), Radius Health (RDUS) and Clovis Oncology (CLVS).

Eagle Pharmaceuticals' stock is owned by a variety of of institutional and retail investors. Top institutional investors include Janus Henderson Group PLC (13.17%), State Street Corp (4.47%), LSV Asset Management (2.70%), Credit Suisse AG (1.77%), Chartwell Investment Partners LLC (1.38%) and AJO LP (1.23%). Company insiders that own Eagle Pharmaceuticals stock include Douglas L Braunstein, Hudson Executive Capital Lp, Sander A Flaum and Scott Tarriff. View Institutional Ownership Trends for Eagle Pharmaceuticals.

EGRX stock was sold by a variety of institutional investors in the last quarter, including LSV Asset Management, Bank of America Corp DE, FMR LLC, Connor Clark & Lunn Investment Management Ltd., Chicago Equity Partners LLC, Man Group plc, Oxford Asset Management LLP and UBS Group AG. Company insiders that have sold Eagle Pharmaceuticals company stock in the last year include Douglas L Braunstein, Hudson Executive Capital Lp and Scott Tarriff. View Insider Buying and Selling for Eagle Pharmaceuticals.

EGRX stock was purchased by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, Goldman Sachs Group Inc., State Street Corp, California Public Employees Retirement System, Schroder Investment Management Group, Janus Henderson Group PLC, Martingale Asset Management L P and Prudential Financial Inc.. View Insider Buying and Selling for Eagle Pharmaceuticals.

Shares of EGRX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of EGRX stock can currently be purchased for approximately $46.31.

Eagle Pharmaceuticals has a market capitalization of $633.06 million and generates $213.31 million in revenue each year. The specialty pharmaceutical company earns $31.90 million in net income (profit) each year or $2.09 on an earnings per share basis. Eagle Pharmaceuticals employs 96 workers across the globe.View Additional Information About Eagle Pharmaceuticals.

The official website for Eagle Pharmaceuticals is http://www.eagleus.com/.

Eagle Pharmaceuticals' mailing address is 50 TICE BOULEVARD SUITE 315, WOODCLIFF LAKE NJ, 07677. The specialty pharmaceutical company can be reached via phone at 201-326-5300 or via email at [email protected]